IDEXX Laboratories (IDXX) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- $4.27
- Estimate
- $3.93
- Surprise
- +8.5%
- Revenue (period 2026-06-30)
- $1.22B
- Score today
- 5.6/10
Revenue source: xbrl.
How the report landed
IDEXX Laboratories (IDXX) beat the $3.93 estimate with diluted EPS of $4.27 — a clear 8.5% upside surprise.
Where TrendMatrix's rating stands now
TrendMatrix currently rates IDXX Buy (Wait) at 5.6/10; no pre/post engine snapshot brackets this report.
4 of the last 4 quarters beat the estimate; this quarter's +8.5% surprise compares with a +5.8% four-quarter average. Next scheduled report: 2026-11-02.
What supports the rating
- V7 flight-to-quality bonus: +0.5 (Q=8.4 in RISK_OFF)
- Sector modifier (Healthcare): +0.5
What argues against it
- Concentration risk — Supplier: Ortho-Clinical Diagnostics
- Expensive valuation
- Negative momentum
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $530.10
- Entry target
- $523.85
- Price target
- $608.06
- Stop
- $493.36
- Upside to target
- +14.7%
- Reward-to-risk
- 2.6:1
The stock trades at 38.3× trailing but 32.2× forward earnings — consensus estimates already build in a substantial earnings recovery.
Model outputs from TrendMatrix’s engine as of 2026-09-04 — shown for context, not personalized investment advice.
IDXX at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Diagnostics & Research
- Market cap
- $42.46B
- P/E (fwd)
- 32.2
- P/E (ttm)
- 38.3
- 52-week range
- $518.55–$769.98
- Off 52-week high
- 31.2%
- RSI (14)
- 40
- Volume vs avg
- 1.16×
- Score today
- 5.6/10